Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

• argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline.

• The transaction supports argenx’s Vision 2030 plan to broaden its presence in autoimmune disease treatment.

• FB102 is expected to be integrated into argenx’s existing research and development programs focused on immunology.

For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI stocks.

argenx is a commercial stage biopharma company focused on therapies for autoimmune diseases across the United States, Japan, China, the Netherlands and other markets, so bringing FB102 into its pipeline fits directly into its effort to broaden its immunology portfolio. With a market cap of €56.1b, it is already a major player in biotech research on immune driven conditions.

Beyond the headline: 3 risks and 3 things going right for argenx that every investor should see.

FB102 deal pushes argenx further into multi-asset immunology

For investors following argenx, bringing FB102 in house supports the Narrative that the company is trying to reduce dependence on a single product while leaning into disease targeting expertise. It lines up with the catalyst that long term growth potential is tied to a broader late stage autoimmune portfolio and to adding differentiated assets that fit its immunology focus. The Forte acquisition also speaks to the company’s willingness to deploy capital into external programs rather than relying only on internal R&D and AI discovery partnerships.

If we take a look at the community Narrative for argenx, we can see how this news fits into the bigger investment story.

The key test for this read is how FB102 progresses once it is inside argenx. Watch for the first clear development milestone that management sets for FB102 under the Vision 2030 plan, along with any concrete timelines or trial designs discussed at upcoming R&D updates and special calls such as the August 2026 ALKIVIA discussion.

For the full picture including more risks and rewards, check out the complete argenx analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARGX.BR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com